Assessing The Value Of Linking Abstracted Medical Record Data With Administrative Claims Data To Study Patients With High-Risk Non-Muscle Invasive Bladder Cancer In The United States

Studying high-risk NMIBC in real-world settings is methodologically challenging because claims data lack the structured pathology and staging information needed to identify HR NMIBC diagnoses, while medical records alone cannot capture long-term outcomes.

Target RWE and Merck researchers developed and evaluated a data linkage approach connecting abstracted medical record data with Komodo Healthcare Map administrative claims to study HR NMIBC patients.

Demonstrating that linked medical record and claims data can characterize HR NMIBC treatment patterns and long-term outcomes provides Merck with a validated data infrastructure for real-world evidence generation for its bladder cancer portfolio.

Multimodal data linkage methodology for HR NMIBC real-world patient characterization and treatment pattern study, Bladder cancer RWE infrastructure supporting Merck oncology portfolio drug development